Buried beneath the Wegovy pill headlines in Novo Nordisk’s third-quarter report is a smaller number with a long backstory. Novo booked a DKK 4.6 billion non-cash impairment on ziltivekimab, the anti-inflammatory antibody it acquired in 2020 as a bet that blocking one immune signal could prevent cardiovascular events. The charge follows the drug’s failure in the ZEUS phase 3 trial in July and the subsequent discontinuation of its heart-failure development program.
The write-down turns a series of scientific setbacks into an accounting fact. It also comes with an important distinction: two heart-failure studies are expected to report results in 2027 despite decisions to end or complete their treatment phases, while a separate trial in patients recovering from heart attacks remains ongoing.
The drug lowered inflammatory markers in a large clinical trial. It did not demonstrate the reduction in cardiovascular events that Novo had hoped for. The financial consequences of that difference are now visible on the company’s balance sheet.
Why Novo Bought an Antibody Designed to Block IL-6
Ziltivekimab is an investigational monoclonal antibody that targets interleukin-6, or IL-6, a protein involved in inflammatory signaling. The premise behind the drug was that reducing IL-6-driven inflammation might lower cardiovascular risk in people who remained vulnerable despite existing treatments.
The idea had scientific appeal. Higher levels of inflammatory biomarkers, including high-sensitivity C-reactive protein, or hsCRP, are associated with increased cardiovascular risk. Researchers have long investigated whether intervening in inflammatory pathways could reduce heart attacks, strokes and cardiovascular deaths.
Novo acquired the drug through its 2020 purchase of Corvidia Therapeutics. The company agreed to pay $725 million upfront, with total potential payments of up to $2.1 billion depending on future regulatory and sales milestones. The deal was intended to strengthen Novo’s cardiovascular development portfolio beyond its established diabetes and obesity businesses.
The ZEUS phase 3 trial was designed to test the clinical hypothesis in a large population. It enrolled more than 6,300 people with atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation, defined by an hsCRP level of at least 2 milligrams per liter.
Participants received once-monthly subcutaneous ziltivekimab 15 mg or placebo on top of standard care. The primary endpoint was the time to the first major adverse cardiovascular event, defined as cardiovascular death, nonfatal heart attack or nonfatal stroke.
These were patients in a cardiovascular outcomes study, not cells or animal models. The trial was intended to determine whether lowering an inflammatory pathway translated into measurable benefits that mattered clinically.
ZEUS Lowered Inflammation but Failed to Reduce Cardiovascular Events
On July 31, 2026, Novo announced that ZEUS had failed its primary endpoint. Ziltivekimab demonstrated the expected biological effect, reducing free IL-6 and hsCRP, but those changes did not translate into a statistically demonstrated reduction in major adverse cardiovascular events.
The primary endpoint analysis produced a hazard ratio of 0.99, with a 95 percent confidence interval of 0.88 to 1.11. A hazard ratio close to 1 indicates that the measured event rates were nearly identical between treatment and placebo groups in this analysis. The confidence interval also included the possibility of no treatment difference.
The result was therefore not simply a missed statistical technicality. It failed to demonstrate the meaningful cardiovascular protection the trial had been designed to establish.
Safety findings added another concern. Novo reported that overall adverse-event and serious-adverse-event rates were similar between groups, but serious infections occurred in a higher proportion of patients receiving ziltivekimab. No difference in all-cause mortality was observed in the headline analysis.
That combination is what makes ZEUS more than a single-drug disappointment. A treatment can engage its intended biological target, move an inflammatory biomarker in the expected direction and still fail to improve the clinical outcomes being measured.
The finding does not demonstrate that inflammation is irrelevant to cardiovascular disease. It shows that this particular method of targeting IL-6 did not provide the expected benefit in the studied population.
Different inflammatory pathways, different patients and different treatment windows may produce different results. But the ZEUS findings challenge the assumption that lowering IL-6 and hsCRP will necessarily reduce cardiovascular events.
The drug lowered the marker. The cardiovascular events did not follow it down.
Why Novo Recorded a DKK 4.6 Billion Impairment
When Novo announced the ZEUS results in July, it warned that the outcome would lead to a non-cash impairment charge in the third quarter. Its November 4 financial report confirmed the amount: DKK 4.6 billion.
The charge reflects the disappointing clinical outlook following ZEUS and the subsequent decisions affecting the HERMES and ATHENA heart-failure studies.
An impairment is an accounting adjustment. It reduces the carrying value of an asset when the company determines that its expected recoverable value is lower than the amount recorded on the balance sheet. The recognition of an impairment does not itself require a new cash payment.
That does not make the loss meaningless. It signals that the company’s assessment of the asset’s future economic potential has deteriorated. In this case, the change follows clinical evidence that significantly weakens the commercial outlook for ziltivekimab.
The DKK 4.6 billion charge sat alongside a DKK 4.1 billion impairment related to the right-sizing of Novo’s manufacturing network. Together, these accounted for DKK 8.7 billion in non-cash impairment charges during the third quarter.
The broader nine-month financial report recorded DKK 15.0 billion in major impairments. That larger figure also included charges associated with monlunabant and other pipeline assets. It should not be confused with the narrower third-quarter impairment total.
The accounting differences help explain the company’s apparently contradictory profit figures. Novo reported that third-quarter operating profit declined 9 percent at constant exchange rates, while adjusted operating profit increased 27 percent at constant exchange rates.
The adjusted figure excludes specified exceptional and non-recurring items. It provides a different view of operating performance, but it does not erase the economic significance of the impairments.
Readers following Novo’s obesity business should keep both measures in view. A company can deliver growth through established products while simultaneously reducing the recorded value of drug-development assets whose prospects have deteriorated.
The impairment is a company putting a financial number on its lowered expectations.
HERMES and ATHENA Were Stopped, While ARTEMIS Continues
ZEUS was only one part of Novo’s late-stage ziltivekimab development program. The company also launched studies examining whether IL-6 inhibition could improve outcomes in patients with heart failure and in patients recovering from acute myocardial infarction.
In July, Novo said the HERMES heart-failure trial and ARTEMIS heart-attack trial were expected to continue, with results anticipated during the first half of 2027.
That assessment changed in September. Following a recommendation from an independent data monitoring committee, Novo moved to discontinue the HERMES and ATHENA heart-failure studies. The committee’s assessment considered the totality of available evidence, including the low likelihood of outcomes differing materially from ZEUS.
Novo’s November 4 report provides the latest distinction. Study treatment in HERMES was discontinued and the trial was closed. In ATHENA, the last participant had completed treatment, and the study was completing as planned.
The company continues to expect readouts from both HERMES and ATHENA during the first half of 2027, with presentations at scientific conferences later that year. However, those expected analyses should not be mistaken for evidence that both treatment programs remain actively progressing toward their original goals.
ARTEMIS remains the separate pivotal study that is continuing. It investigates ziltivekimab in people following acute myocardial infarction, a different clinical situation from the chronic cardiovascular risk studied in ZEUS.
The distinction matters because an acute heart attack produces a different inflammatory environment from the persistent, lower-grade inflammation associated with chronic atherosclerotic and kidney disease. Whether blocking IL-6 in that setting produces a useful clinical effect remains unknown.
Novo’s current timetable anticipates ARTEMIS phase 3 results in the first half of 2027. A positive result could reopen questions about where ziltivekimab might have a role, while another negative result would further undermine the case for continuing development.
The remaining trials therefore do not offer three interchangeable chances to rescue the program. Two heart-failure studies are approaching readout after discontinuation or completion of treatment. ARTEMIS is the ongoing test of the antibody in an acute heart-attack population.
What the Setback Means for the Cardiometabolic Drug Race
Novo and Eli Lilly are both attempting to turn their metabolic medicines into broader cardiometabolic franchises. Their development strategies increasingly connect weight management, diabetes treatment, cardiovascular disease and kidney health.
Evidence that GLP-1-based medicines can improve cardiovascular outcomes has strengthened that strategy. Real-world research continues to examine how different treatments compare in clinical practice, as we covered in our report on Ozempic and Mounjaro cardiovascular outcomes.
Ziltivekimab represented a different opportunity. Rather than primarily acting through metabolic pathways, the antibody targeted IL-6-driven inflammation as a separate mechanism for reducing cardiovascular risk.
That made the program strategically valuable. If successful, it could have broadened Novo’s cardiovascular portfolio beyond the GLP-1 treatments responsible for much of its existing commercial strength.
Its setbacks illustrate the difficulty of expanding a pharmaceutical portfolio into adjacent biological mechanisms. A scientifically credible target can produce encouraging biomarker changes without delivering clinical benefit in a large outcomes trial.
The pattern extends beyond Novo. Other large drugmakers have also reduced investment in experimental cardiometabolic programs after disappointing data, including Roche’s decision concerning emugrobart, which we covered in our report on Roche’s terminated muscle-preservation program.
Those examples involve different mechanisms and should not be treated as proof that one scientific approach predicts the outcome of another. They illustrate a common business reality: pharmaceutical companies must repeatedly reassess development investments as more reliable evidence becomes available.
Several questions remain open. The detailed ZEUS data will be important for assessing the seriousness of the infection signal and possible differences among patient subgroups. The HERMES and ATHENA analyses may help clarify the consequences of the early study decisions. And the ARTEMIS results will test whether the antibody performs differently after an acute heart attack.
The broader relationship between inflammation and cardiovascular disease remains an active field of research. ZEUS tested one antibody, one inflammatory pathway and one defined patient population. The result was disappointing, but it does not settle every question about anti-inflammatory cardiovascular treatment.
For now, the DKK 4.6 billion impairment is Novo’s clearest financial acknowledgment that ziltivekimab’s prospects have substantially worsened. The remaining analyses may reveal important biological information. Only convincing clinical outcomes can establish whether the molecule still has a meaningful therapeutic future.
The marker moved. The clinical benefit did not follow. The accounting has now caught up.
Primary financial source: Novo Nordisk financial report for the first nine months of 2026, published November 4, 2026.
Detailed financial and R&D disclosure: Novo Nordisk Company Announcement No. 65/2026, including updated HERMES, ATHENA and ARTEMIS development timelines.
Original ZEUS results: Novo Nordisk provides update on the ZEUS phase 3 trial, July 31, 2026.
Acquisition history: Novo Nordisk to acquire Corvidia Therapeutics, June 11, 2020.
Trial discontinuation reporting: STAT — Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation, September 7, 2026.
